Table 2.
Number (n) of users of the most commonly used drugs classified as P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) substrates (S) or inhibitors (I) in the P‐pg/BCRP polytherapy group
| Drug | n | P‐gp transporter substrate/inhibitor | BCRP transporter substrate/inhibitor |
|---|---|---|---|
| Cetirizine | 3242 | S, I | |
| Progesterone | 2985 | I | |
| Oestradiol (17‐β) | 2813 | I | |
| Fluticasone (nasal) | 2765 | S | |
| Azithromycin | 2369 | S, I | |
| Fluticasone (inhalation) | 1976 | S | |
| Budesonide (inhalation) | 1955 | S | |
| Prednisolone | 1893 | S | |
| Citalopram | 1835 | S, I | |
| Diclofenac | 1426 | S, I | |
| Omeprazole | 1202 | S, I | I |
| Pantoprazole | 1137 | S, I | S, I |
| Loratadine | 1028 | S | |
| Roxithromycin | 1020 | S, I | |
| Desloratadine (descarboethoxyloratadine) | 973 | S | |
| Clarithromycin | 805 | S, I | |
| Levocetirizine ((R)‐cetirizine) | 787 | S | |
| Sertraline | 757 | I | |
| Propranol | 749 | I | |
| Sulfasalazine | 741 | S | S, I |
| Montelukast | 725 | I | |
| Quetiapine | 717 | I | |
| Ranitidine | 717 | S | |
| Lansoprazole | 715 | S, I | I |
| Metformin | 710 | S | S |
| Erythromycin | 586 | S, I | S |
| Prednisone | 537 | S | |
| Ciprofloxacin | 469 | S | S |
| Methylprednisolone | 458 | S | I |
| Etoricoxib | 449 | I |